The identified novel KIR2DS4:HLA-B*35 interaction axis predicts patient survival, in both haplo-identical and fully matched, HCT and highlights that the current understanding of the KIR:HLA interactome is incomplete and requires remapping for enhanced therapeutic applications.
Abstract
Haplo-identical hematopoietic cell transplantation (haploHCT) is an integral treatment paradigm for patients with leukemia. While overall survival (OS) post-haploHCT has steadily improved, relapse-free survival (RFS) remains relatively stagnant. Upon the discovery of killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells and their cognate human leukocyte antigen (HLA) ligands, algorithms have been developed to enhance graft versus leukemia effects. However, these algorithms fail to yield consistent predictions in patient outcomes. We utilized a combination of in silico protein folding and interactions to determine KIR:HLA reactivity in conjunction with in vitro acoustic force microscopy to measure cell avidity (CA) as a readout for KIR signal strength. CA was determined using monoallelic HLA expressing K562 cell lines, monoallelic KIR Jurkat cells, and peripheral blood NK cells. We extended the CA results and performed standard cytotoxicity assays as well. We discovered that HLA-B*35 interacts with KIR2DS4. We applied the newly discovered interaction to predict outcomes for HCT patients. Stratifying patients based on their HLA-B*35 positivity and donor KIR2DS4 status, we delineated a correlation to survival (P=0.061) when donors only had full-length KIR2DS4. Patients who received a haploHCT and NK cell addback from donors with only full-length KIR2DS4 had a significantly improved RFS (P=0.001) and OS (P=0.016) compared to truncated (KIR1D) and full-length KIR2DS4 donors. This was independently validated in a diverse 10/10 HLA matched European cohort with RFS (P=0.0255) and OS (P=0.0388). Thus, the identified novel KIR2DS4:HLA-B*35 interaction axis predicts patient survival, in both haplo-identical and fully matched, HCT and highlights that our current understanding of the KIR:HLA interactome is incomplete and requires remapping for enhanced therapeutic applications.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a poor prognosis and an unmet need for more effective treatment options, particularly after relapse. One potential approach to address this need, which has been used successfully in solid tumors, is adoptive transfer of T cells enginee...
Aidan Pursley, Uns Kirmani, Amanda L. C. Chen et al.· bioRxiv· 0 citations
BACKGROUND
Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like recepto...
I. Ruiz-Lorente, Andrés Vallejo-Pulido, A. López-Abad et al.· Oncoimmunology· 0 citations
Introduction Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I molecule that functions as an immune checkpoint via inhibitory receptors such as immunoglobulin-like transcript 2 (ILT2), immunoglobulin-like transcript 4 (ILT4) and killer cell immunoglobulin-like receptor 2DL4 (...
Alexandra Epp, M. Serrano-Serrano, Florian Heil et al.· Frontiers in Immunology· 0 citations
Immune checkpoint inhibitors (ICIs) benefit only a minority of patients with advanced non-small cell lung cancer (NSCLC). Whether germline human leukocyte antigen (HLA) or killer cell immunoglobulin-like receptor (KIR) variation identifies them is unclear, partly because studies define HLA exposures differently. We ask...
Andrea González-Hernández, Alberto Ríos, J. L. Onieva et al.· International Journal of Mol...· 0 citations
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies and multiple myeloma, but its extension to T-cell lymphomas (TCLs) has been constrained by the paucity of antigens that can be safely targeted. While targeting pan-T antigens broadens the therapeutic reach across various...
Federico Mario Aletti, J. Weng, Cuong Le et al.· bioRxiv· 0 citations
Introduction Natural killer (NK) cell alloreactivity at the maternal–fetal interface is regulated by killer cell immunoglobulin-like receptors (KIR) and CD94/NKG2A receptors. A dimorphism at position −21 of the HLA-B leader peptide (−21M/−21T) biases NK education toward NKG2A (when −21M supplies HLA-E–binding peptides)...
R. G. Laborda, Nabil Subhi-Issa, E. de la Fuente-Muñoz et al.· Frontiers in Immunology· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 9, 2026
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.